Counterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancer

The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: William J. Gradishar, MD, Northwestern University, Feinberg School of Medicine, 676 North St. Clair, Suite 850, Chicago, IL 60611. E-mail: w-gradishar@northwestern.edu
  • 1.

    FossatiRConfalonieriCTorriV. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol1998;16:34393460.

    • Search Google Scholar
    • Export Citation
  • 2.

    CarrickSParkerSWilckenN. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev2005;CD003372.

    • Search Google Scholar
    • Export Citation
  • 3.

    O'ShaughnessyJMilesDVukeljaS. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol2002;20:28122823.

    • Search Google Scholar
    • Export Citation
  • 4.

    O'ShaughnessyJNagSCalderillo-RuizG. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol2003;22(Suppl 1):Abstract 25.

    • Search Google Scholar
    • Export Citation
  • 5.

    AlbainKSNagSCalderillo-RuizG. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as front-line therapy for metastatic breast cancer (MBC): first report of overall survival [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 6.

    MilesDVukeljaSMoiseyenkoV. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer2004;5:273278.

    • Search Google Scholar
    • Export Citation
  • 7.

    SledgeGWNeubergDBernardoP. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol2003;21:588592.

    • Search Google Scholar
    • Export Citation
  • 8.

    SmalleyRVMurphySHuguleyCMBartolucciAA. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res1976;36:39113916.

    • Search Google Scholar
    • Export Citation
  • 9.

    YamamotoNWatanabeTKatsumataN. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol1998;16:24012408.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 37 32 3
PDF Downloads 17 15 0
EPUB Downloads 0 0 0